IAM Life Sciences 2021: Legal tech and biotech patents

Geschreven door Dietmar Hertsen

-Dit artikel is alleen in het Nederlands beschikbaar- Patents are a true form of capital: nice to have, hard to get and looking at others will rarely make you happy. Part of this equation is the impenetrable ‘patentese’ that one must embrace while drafting and analysing patents and patent applications. Is there a shortcut?

In its most disruptive form, AI has the potential to render the patent literature a standardised, machine-readable library, changing the tide for patent practitioners and refocusing the role of patents in biotech

IAM Life Sciences

NLO's patent attorney Dietmar Hertsen wrote an article for the 2021 edition of 'IAM Life Sciences: Key issues for senior life sciences executives 2021'. To read the full article, click on the link below.

IAM Life Sciences: Legal tech and biotech patents

Credits

This article first appeared in IAM Life Sciences: Key issues for senior life sciences executives 2021, a supplement to IAM, published by Globe Business Media Group - IP Division. To view the guide in full, please to the website of IAM.

About the author

Dietmar Hertsen Nederlands en Europees octrooigemachtigde